Tobacco use among individuals with schizophrenia: What role has the tobacco industry played?

Schizophrenia Bulletin

Volumn 34, Issue 3, 2008, Pages 555-567

  Prochaska, Judith J ^a   Hall, Sharon M ^a   Bero, Lisa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cigarettes; Mentally ill; Nicotine; Psychiatry; Smoking; Tobacco companies

Indexed keywords

ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; HEALTH BELIEF; HUMAN; NEEDS ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF MEDICATION; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; TOBACCO INDUSTRY; CULTURAL ANTHROPOLOGY; REVIEW; SMOKING;

CULTURE; HUMANS; SCHIZOPHRENIA; SMOKING; TOBACCO INDUSTRY; TOBACCO USE DISORDER;

EID: 49049093102     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm117     Document Type: Article

References (179)

1. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:1107-1115.
2. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-2610.
3. Federal Trade Commission.Federal Trade Commission Cigarette Report for 2003. Washington, DC: Federal Trade Commission; 2005.
4. Womach J. U.S. Tobacco Production, Consumption, and Export Trends (Report for Congress Received Through the CRS Web). 2003. Congressional Research Service.The Library of Congress. Available at: http://www. nationalaglawcenter.org/assets/crs/RL30947.pdf.
5. Hughes JR. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry. 1993;54:109-114.
6. Poirier MF, Canceil O, Bayle F, et al. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:529-537.
7. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429-436.
8. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005;104:2817-2821.
9. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res. 1996;22:133-141.
10. Sandyk R, Kay SR. Tobacco addiction as a marker of age at onset of schizophrenia. Int J Neurosci. 1991;57:259-262.
11. Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003;24:267-288.
12. Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005;120:200-208.
13. Carter SM. Tobacco document research reporting. Tob Control. 2005;14:368-376.
14. Lewis NDC. Research in Dementia Praecox.Bates No. HK2333032/3032. Available at: http://legacy.library.ucsf.edu/tid/veq2aa00. 1955.
15. Modrzewska K, Book JA. Schizophrenia and malignant neoplasms in a north Swedish population. Lancet. 1979;1:275-276 Bates No. 10412696B/2697. Available at: http://legacy.library.ucsf.edu/tid/yjp4aa00.
16. Gopalaswamy AK, Morgan R. Smoking in chronic schizophrenia correspondence. Br J Psychiatry. 1986;149:523 Bates No. 508153978. Available at: http://legacy.library.ucsf.edu/tid/ncj13a00.
17. Jancar J. Cancer in the long-stay hospitals. Br J Psychiatry. 1979;134:550-551Bates No. 2025876464/6465. Available at: http://legacy.library. ucsf.edu/tid/ams24e00.
18. Rice D. No lung cancer in schizophrenics? Br J Psychiatry. 1979;134:128Bates No. 501729733. Available at: http://legacy.library.ucsf.edu/ tid/rog23a00.
19. Lincoln JE. Schizophrenics.Bates No. 1005062041/2042. Available at: http://legacy.library.ucsf.edu/tid/yrt53e00. 1983.
20. Perrin GM, Pierce IR. Psychosomatic aspects of cancer: a review. Psychosom Med. 1959;21:397-421.
21. Breen MJ. The incidence of lung cancer among schizophrenic males versus nonschizophrenic males. A dissertation presented to the graduate faculty of the School of Education United States International University. 1981. Bates No. 504848496/8514. Available at: http://legacy.library.ucsf.edu/tid/cuq18c00.
22. Fox BH, Howell MA. Cancer risk among psychiatric patients: a hypothesis. Int J Epidemiol. 1974;3:207-208.
23. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983;44:42-46.
24. Harris AE. Physical disease and schizophrenia. Schizophr Bull. 1988;14:85-96.
25. Bahnson CB. Letter to Dr. Hockett Requesting Continued Research Funding on Dr. Kissen's Unit in Glasgow.August 8, 1967. Bates No. CTRSP/FILES003163/3164. Available at: http://legacy.library.ucsf.edu/tid/ nid8aa00.
26. Hetsko C. Memo to William W. Shinn Confirming American Brands' $8,000 Contribution to Dr. Claus Bahnson's Project. September 15, 1972. Bates No. 945369841/9842. Available at: http://legacy.library.ucsf.edu/ tid/dxj51a00.
27. Holtzman A. Special Project - Dr. Claus Bahnson. August 23, 1972. Bates No. 1005135608. Available at: http://legacy.library.ucsf.edu/tid/ccr87e00.
28. Parfitt DN. Lung cancer and schizophrenia. Br J Psychiatry. 1981;138:179-180. Bates No. 1003050027/0028. Available at: http://legacy. library.ucsf.edu/tid/anp97e00.
29. Colby FG. Report on trip to Germany.June 12, 1980. Bates No. 500926090-500926097. Available at: http://legacy.library.ucsf.edu/tid/qax61d00.
30. Marcus MG. The shaky link between cancer and character. Psychol Today. 1976;10:52,54,59,85. Bates No. 2023065144/5147. Available at: http://legacy.library.ucsf.edu/tid/qnk48e00.
31. Wakeham H. Letter about Doubts of Dr. Bahnson's Research Involvement.April 16, 1971. Bates No. 1003728541. Available at: http://legacy.library.ucsf.edu/tid/dlq08e00.
32. Todd GF. Private Letter No. 12 to Mr. Addison Yeaman. April 14, 1967. Bates No. 2015063868/3870. Available at: http://legacy.library.ucsf.edu/ tid/krp78e00.
33. Gaudet FJ, Owen HE. Application for Research Grant Exploring Cancer Rates and Cigarette Use among Different Types of Schizophrenia. January 24, 1964. Bates No. 01128311/8314. Available at: http://legacy.library.ucsf.edu/tid/ huz71e00.
34. Lavietes MH. Cigarette Smoking in Schizophrenic Patients. February 12, 1997. Bates No. 50533019/3021. Available at: http://legacy.library.ucsf. edu/tid/hdx06d00.
35. Hockett RC. Research Application from Frederick J. Gaudet. August 5, 1965. Bates No. HK0352042/2042. Available at: http://legacy.library.ucsf.edu/ tid/bkv9aa00.
36. McAllister HC. Decline of Research Support for Dr. Marc Lavietes. April 14, 1997. Bates No. 50532999/2999. Available at: http://legacy.library. ucsf.edu/tid/nwv06d00.
37. CTR Collection.Confidential Report Scientific Advisory Board Meeting New York, NY. March 8, 1964. Bates No. CTRMIN/SAB000222/0225. Available at: http://legacy.library.ucsf.edu/tid/vix30a00.
38. CTR Collection. New proposals. 1964. Bates No. HK2039136/9136. Available at: http://legacy.library.ucsf.edu/tid/gvo2aa00.
39. Hockett RC. Letter to Dr. Taguiri Concerning Research Proposals, Including Smoking and High Academic Achievement. March 11, 1964. Bates No. HK1507074/7074. Available at: http://legacy.library.ucsf.edu/tid/sgh2aa00.
40. Wilson EB. Letter to Dr. Hockett.March 15, 1964. Bates No. HK1507061/7062. Available at: http://legacy.library.ucsf.edu/tid/kgh2aa00.
41. Dalton SO, Laursen TM, Mellemkjaer L, Johansen C, Mortensen PB. Risk for cancer in parents of patients with schizophrenia. Am J Psychiatry. 2004;161:903-908.
42. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58:573-578.
43. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
44. Himelhoch S, Lehman A, Kreyenbuhl J, Daumit G, Brown C, Dixon L. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry. 2004;161:2317-2319.
45. Gullotta. WSA Categorization form Smoking Behavior: Clinical Depression and Schizophrenia.October 20, 1999. Bates No. 2074168169/8170. Available at: http://legacy.library.ucsf.edu/tid/qbl45c00.
46. Southwick MA. Literature Search: Schizophrenia and Nicotine. March 6, 1997. Bates No. 2075745247. Available at: http://legacy.library.ucsf.edu/ tid/clq60c00.
47. Glantz SA, Slade J, Bero LA, Hanauer P, Barnes DE. The Cigarette Papers. Berkeley, Calif: University of California Press; 1996.
48. Deithelm PA, Rielle J-C, McKee M. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet. 2005;366:86-92.
49. Knott V. Tobacco Smoking as a Coping Mechanism in Psychiatric Patients: Psychological, Behavioral and Physiological Investigations Phase I. April 18, 1983. Bates No. 1002647660/7696. Available at: http://legacy.library.ucsf.edu/tid/twb64e00.
50. Knott V. Research Proposal. Tobacco Smoking as a Coping Mechanism in Psychiatric Patients: Psychological, Behavioral and Physiological Investigations.April 11, 1983. Bates No. 504332664/2666. Available at: http://legacy.library.ucsf.edu/tid/lrg58d00.
51. Crawford DA. Letter to Dr. R. Suber in the Consideration Dr. Knott's Research Proposal.May 1, 1985. Bates No. 504195870/5871. Available at: http://legacy.library.ucsf.edu/tid/bsr58d00.
52. Barnes DE, Bero LA. Industry-Funded Research and Conflict of Interest: An Analysis of Research Sponsored by the Tobacco Industry through the Center for Indoor Air Research. J Health Polit Policy Law. 1996;21:515-542.
53. Bero L, Barnes DE, Hanauer P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. JAMA. 1995;274:241-247.
54. Amey MB, Wong DF. Application for Research Grant: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain. November 26, 1986. Bates No. 40047640/7657. Available at: http://legacy.library.ucsf.edu/tid/qvz46d00.
55. Smith C. Comments on Dr. Wang's Grant Proposal: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain. September 18, 1987. Bates No. 40047615/7619. Available at: http://legacy.library.ucsf.edu/tid/ cks99c00.
56. Stone D. Second Renewal Application: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain.July 11, 1989. Bates No. 40047549/7549. Available at: http://legacy.library.ucsf.edu/tid/kzr99c00.
57. Gray JA. CTR Progress Report Mediation by Catecholamine Systems of Effects of Nicotine on Behaviours. Bates No. 50716862/6864. Available at: http://legacy.library.ucsf.edu/tid/gqg46d00.
58. Gray JA. Project Details: Nicotine Neuroprotection and Animal Models of Neurodegenerative Cognitive Dysfunction. Bates No. 566948811. Available at: http://legacy.library.ucsf.edu/tid/prx11c00.
59. Gray JA, Joseph MH, Hemsley DR, et al. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res. 1995;71:19-31. Bates No. 50379603/9615. Available at: http://legacy.library. ucsf.edu/tid/iek98d00.
60. Postma P, Gray JA, Sharma T, et al. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl). 2006;184:589-599.
61. Mangan GL. Application to Philip Morris USA for Research Funding. October, 1994. Bates No. 2050754698/4704. Available at: http://legacy.library. ucsf.edu/tid/dcm79e00.
62. Mangan GL. Facsimile Transmission Header Sheet Completion of Philip Morris Research Programme at the University of Auckland.September 25, 1995. Bates No. 2051517565/7568. Available at: http://legacy.library.ucsf.edu/tid/ umw14c00.
63. Hedqvist P, Svensson TH. Research Grant Application. Nicotine Dependence in Psychiatric Illness: an Experimental Study. May 24, 1994. Bates No. 50708221/8247. Available at: http://legacy.library.ucsf.edu/tid/ xuf46d00.
64. Glenn JF. Brief Site Visit Report.July 18, 1989. Bates No. 60037022/7022. Available at: http://legacy.library.ucsf.edu/tid/bkz20a00.
65. Svensson TH. CTR Progress Report (for Competing Renewal Application) Nicotinic Dependence in Psychiatric Illness: an Experimental Study. December 31, 1997. Bates No. 50733862/3868. Available at: http://legacy.library.ucsf. edu/tid/kxi46d00.
66. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha1-adrenoreceptor antagonism. J Clin Psychopharmacol. 1995;15:(suppl 1):11S-18S. Bates No. 50733819/3826. Available at: http://legacy.library.ucsf.edu/tid/ixi46d00.
67. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994;16:36-44. Bates No. 50708314/8314. Available at: http://legacy.library.ucsf.edu/tid/luf46d00.
68. Nisell M, Nomikos GG, Svensson TH. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol. 1994;75:348-352.
69. Nisell M, Nomikos GG, Svensson TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol. 1995;76:157-162.
70. Grillner P, Bonci A, Svensson TH, Bernardi G, Mercuri NB. Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. Neuroscience. 1999;91:557-565.
71. Furlong P, Tanabe J. Project Proposal Effects of Nicotine on Brain Activation. February 1, 1999. Bates No. 2072044334/4360. Available at: http://legacy.library.ucsf.edu/tid/len06c00.
72. Kassman A. SRRC Proposals: Tanabe, Bilder & Lajtha/Friedman. November 27, 1998. Bates No. 2076627440. Available at: http://ltdlimages. library.ucsf.edu/imagesm/m/h/e/mhe87d00.
73. Gullotta FP. Bilder/Lajtha Grant. March 13, 2000. Bates No. 2078527898/7899. Available at: http://legacy.library.ucsf.edu/tid/lel75c00.
74. Philip Morris Collection.Approval of Grant Proposal Entitled: "Effects of Nicotine on Brain Activation".February 8, 2001. Bates No. 2081497294. Available at: http://legacy.library.ucsf.edu/tid/uwu82c00.
75. McAlpin L. Philip Morris Voucher. January 11, 1999. Bates No. 2064324795. Available at: http://legacy.library.ucsf.edu/tid/hmt08d00.
76. Bidler RM, Lajtha A, Thomas T. Nicotine Effects on Cognition: Meta-analysis and Implications for Neuroimaging. Abstract presented at the annual meeting of the American College of Neuropsychopharmacology. December, 1999. Bates No. 2074597992. Available at: http://legacy.library.ucsf.edu/tid/ ifl60c00.
77. de Leon J. Epidemiology of Tobacco Use in Psychiatric Disorders. Bates No. 682349577/9582. Available at: http://legacy.library.ucsf.edu/tid/ cyb01c00.
78. Esser AH, Lee MG. Application for Research Grant: The Social Use of Tobacco. August 8, 1966. Bates No. 50080837/0845. Available at: http://legacy.library.ucsf.edu/tid/qtf9aa00.
79. Hoyt WT. Research Funding Decline for Dr. Aristide H. Esser. September 20, 1966. Bates No. 50080835/0835. Available at: http://legacy. library.ucsf.edu/tid/otf9aa00.
80. Smith RC. Effects of Smoking on Blood Levels of Neuroleptic and Antidepressant Drugs. November 22, 1977. Bates No. 50264775/4790. Available at:http://legacy.library.ucsf.edu/tid/dki89c00.
81. Goff DC. Nicotine in Schizophrenia. July 2, 1991. Bates No. 50596565/6567. Available at: http://legacy.library.ucsf.edu/tid/brq36d00.
82. Barclay GL, Devlin RJ, Grant FW, McDonald RD, Ozerengin MF, Voorhees W. Application for Research Grant: Vitamin "C" Depletion in Tobacco Smokers. Influence on Psychopathology and Therapeutic Drug Requirements in a Mental Hospital Setting. November 14, 1972. Bates No. 50197194/7208. Available at: http://legacy.library.ucsf.edu/tid/jrc79c00.
83. Deutsch SI. Effect of Nicotine in an Animal Model of Schizophrenia. February 15, 1996. Bates No. 50521602/1604. Available at: http://legacy.library.ucsf.edu/tid/etr06d00.
84. Lachman H. Molecular Genetic Analysis of Aggression in Rats.August 13, 1996. Bates No. 50532660/2662. Available at: http://legacy.library.ucsf. edu/tid/six06d00.
85. Javaid JI, Longone P, Pesold C. Functional Characterization of Neuronal Nicotinic Acetylcholine Receptor (NACHR) Subtypes. February 14, 1997. Bates No. 50529673/9675. Available at: http://legacy.library.ucsf.edu/tid/ trv06d00.
86. Liu Y, Nisbett N. Research Grant Application: Physiological Role(s) of SNAP-25. November 29, 1995. Bates No. 50387789/7800. Available at: http://legacy.library.ucsf.edu/tid/nym98d00.
87. Nawa H. Neurotransmitter Differentiation of Neural Precursors in the Brain. January 30, 1993. Bates No. 50617622/7624. Available at: http://legacy.library.ucsf.edu/tid/lgm26d00.
88. Paskevich PA, Tarazi FI. Research Grant Application Localization and Regulation of Neurotensin Receptor and Gene Expression. May 28, 1997. Bates No. 40045371/5385. Available at: http://legacy.library.ucsf.edu/tid/icr99c00.
89. Regehr WG. The Control of Synaptic Transmission in the Mammalian Brain by Presynaptic Waveform. August 13, 1996. Bates No. 50543076/3078. Available at: http://legacy.library.ucsf.edu/tid/wrb16d00.
90. Arnason B. Drug abuse and the Dopamine Transporters. March 29, 1994. Bates No. 50494964/4965. Available at: http://legacy.library.ucsf.edu/tid/ jle06d00.
91. Tarazi FI. Pharmacological and Functional Characterization of Dopamine D4 Receptor. 1996. Bates No. 50549783/9786. Available at: http://legacy.library.ucsf.edu/tid/cok36d00.
92. RJ Reynolds Collection. Review of a Proposal Submitted by Sheila Carter, M.D. 1985. Bates No. 504808412/8413. Available at: http://legacy.library.ucsf.edu/tid/stm55d00.
93. Callery PS. Metabolites of Tobacco Constituents Related to GABA as Potential Therapeutic Entities. Bates No. 1625002-1625003. Available at: http://legacy.library.ucsf.edu/tid/hdm20a00.
94. Ellis C. WWSA Project Justification Role of Neuronal Nicotinic Receptors in Brain Function. January 5, 1998. Bates No. 20725972780. Available at: http://legacy.library.ucsf.edu/tid/ffw95c00.
95. Hayes AW. Letter to Dr. D.A. Crawford Concerning Review of Research Grants. August 19, 1985. Bates No. 504198469. Available at: http://legacy.library.ucsf.edu/tid/kor58d00.
96. Hockett RC. Research Proposal Decline for Robert C. Smith. October 24, 1978. Bates No. 50264764/4764. Available at: http://legacy.library.ucsf. edu/tid/sji89c00.
97. Glenn JF. Rejection for Dr. Neve's Research Proposal: Drug Abuse and the Dopamine Transporter.April 25, 1994. Bates No. 50494962/4962. Available at: http://legacy.library.ucsf.edu/tid/hle06d00.
98. Glenn JF. Decline of Dr. Yuechueng Liu's Research Proposal: Physiological Role(s) of SNAP-25.April 24, 1996. Bates No. 50387782/7782. Available at: http://legacy.library.ucsf.edu/tid/jym98d00.
99. Glenn JF. Rejection of Dr. F. Tarazi's Research Proposal: Localization and Regulation of Neurotensin Receptor and Gene Expression.April 24, 1997. Bates No. 50404261/4261. Available at: http://legacy.library.ucsf.edu/tid/ xat98d00.
100. McAllister HC. Decline of Research Funds for Donald C. Goff. July 25, 1991. Bates No. 50596550/6550. Available at: http://legacy.library.ucsf.edu/ tid/uqq36d00.
101. McAllister HC. Decline of Support for Dr. Wade Regehr's Research Proposal. October 1, 1996. Bates No. 50543046/3046. Available at: http://legacy.library.ucsf.edu/tid/uhd16d00.
102. Lippiello PM, Fluhler EN. Nicotine Receptor Pharmacology. June, 1989. Bates No. 507973662/3665. Available at: http://legacy.library.ucsf.edu/ tid/uva14d00.
103. Lillpiello PM, Caldwell WS, DeBethizy JD, Smith CJ, Pritchard WS. Progress Report on the RJRT-Hoechst-Roussel Collaborative Scientific Program. January 16, 1991. Bates No. 508209460/9503. Available at: http://legacy.library.ucsf.edu/tid/guf04d00.
104. Wellesley MA. Corporate Overview of Pharmaceutical Related Technologies of the R.J. Reynolds Tobacco Company. March, 1997. Bates No. 516889375/9378. Available at: http://legacy.library.ucsf.edu/tid/gxh56d00.
105. Targacept.Targacept Key Messages.March 18, 1999. Bates No. 530420558/0616. Available at: http://legacy.library.ucsf.edu/tid/oxd35a00.
106. Vagg R, Chapman S. Nicotine analogues: a review of tobacco industry research interests. Addiction. 2005;100:701-712.
107. Targacept. Targacept Pharmaceutical Technologies of the R.J. Reynolds Tobacco Company. August 31, 1999. Bates No. 529222194/2321. Available at: http://legacy.library.ucsf.edu/tid/moi25a00.
108. Targacept.Targacept Leader in Neuronal Nicotinic Receptor-Based pharmaceutical R&D. August, 2000. Bates No. 2085792578/2589. Available at: http://legacy.library.ucsf.edu/tid/ovn20c00.
109. Hwang S. "R.J. Reynolds Hopes to Spin Nicotine Into Drugs". Wall St J. 1999. Jun 28:Sect. B1. Bates No. 535070496/0497. Available at: http://legacy.library.ucsf.edu/tid/hzp11c00.
110. RJ Reynolds Collection. Nicotinic Compound Q&A. January 15, 1999. Bates No. 521107424/7431. Available at: http://legacy.library.ucsf.edu/ tid/sfe50d00.
111. US Department of Health & Human Services FDA/Center for Drug Evaluation and Research.A Catalog of FDA Approved Drug Products. 2006 [cited 1/17/2006]. Available from: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/.
112. Philip Morris Collection.Advertisement: schizophrenic. The new merit. We've got flavor down to a science. 1986. Bates No. 2040270976. Available at: http://legacy.library.ucsf.edu/tid/qrz74e00.
113. Gilbert DG. Smoking: Individual Differences, Psychopathology, and Emotion. Washington, DC: Taylor & Francis; 1995.
114. Rosecrans JA. Nicotine: helping those who help themselves? Chem Ind. 1998;525-529. Bates No. 2063591851/1855. Available at: http://legacy.library.ucsf.edu/tid/ryp67e00.
115. Tobacco Institute Collection.Active Projects. Bates No. CORTI0007337/7346. Available at: http://legacy.library.ucsf.edu/tid/wei30c00.
116. American Tobacco Collection. Projects Supported 1977. Bates No. 966003844/3850. Available at: http://legacy.library.ucsf.edu/tid/osg60a00.
117. Council for Tobacco Research. Report of the Council for Tobacco Research USA Inc. 1992. Bates No. TIMN0397062/7351. Available at: http://legacy.library.ucsf.edu/tid/csi62f00.
118. Nixon G. Fax. May 2, 1994. Bates No. 2029238971. Available at: http://legacy.library.ucsf.edu/tid/hee69e00.
119. Philip Morris Collection. Pharmacology of Nicotine. May, 1994. Bates No. 2029238974. Available at: http://legacy.library.ucsf.edu/tid/aee69e00.
120. Levin ED. Thank You to Robert F. Gertenbach for $75,000/ year Grant Concerning the Behavioral and Neural Mechanisms Underlying Nicotine-Induced Cognitive Facilitation. November 8, 1991. Bates No. 50689418/9418. Available at: http://legacy.library.ucsf.edu/tid/grv26d00.
121. Levin ED. Thank You to Dr. Robert F. Gertenbach for $85,000 Grant to Investigate Beneficial Effect Nicotine Has on Memory Function. October 21, 1992. Bates No. 50689408/9408. Available at: http://legacy.library. ucsf.edu/tid/zqv26d00.
122. Levin ED. Thank You for $43,777 Gift to Support Work on Nicotinic Psychopharmacology at Duke. December 15, 1995. Bates No. 515718437. Available at: http://legacy.library.ucsf.edu/tid/xie01d00.
123. Levin ED. Thank You to Dr. McAllister for $92,000 Grant to Investigate Beneficial Effect Nicotine Has on Memory Function. January 3, 1994. Bates No. 60038721/8721. Available at: http://legacy.library.ucsf.edu/tid/ ola30a00.
124. Levin ED, Karan L, Rosecrans J. Nicotine: an addictive drug with therapeutic potential. Med Chem Res. 1993;509-513.
125. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol. 2000;393:141-146.
126. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets. 2002;1:423-431.
127. Levin ED. Nicotinic receptors in the nervous system. New York, NY: CRC Press. Chapter 11 by Joseph McEvoy Nicotine and Schizophrenia, 2001; 227-234.
128. Levin ED. Letter to RJR's Dr. J. Donald DeBethizy Requesting $15,000 for Duke's Nicotine Research Symposium.May 2, 1995. Bates No. 515718445. Available at: http://legacy.library.ucsf.edu/tid/yob40d00.
129. Levin ED. Thank You to Dr. Frank Gullotta of Phillip Morris-USA for $10,000 Donation to Duke Nicotine Conference. August 4, 1998. Bates No. 2063120664. Available at: http://legacy.library.ucsf.edu/tid/ptg33e00.
130. Levin ED. Request for Monetary Contribution for Duke Nicotine Conference from Dr. Frank Gullotta of Phillip Morris-USA. July 22, 1999. Bates No. 2084272438. Available at: http://legacy.library.ucsf.edu/tid/tvs19c00.
131. Levin ED. First Annual Duke Nicotine Research Symposium. Neurobehavioral Effects of Nicotine. November 8, 1995. Bates No. 516546711/6713. Available at: http://legacy.library.ucsf.edu/tid/cxs90d00.
132. Philip Morris Collection. Synopsis of the 5th Annual Duke Nicotine Research Conference.October 22, 1999. Bates No. 2074407740/7741. Available at: http://legacy.library.ucsf.edu/tid/wgr17d00.
133. Rose JE, Levin ED. Duke Nicotine Research Conference. Available at: http://psychiatry.mc.duke.edu/nicotineresear/Conf.html. Accessed October 8, 2007.
134. Brandt L, Brearley E. Future Events: 5th Annual Duke Nicotine Research Conference, Targeting Nicotinic Treatments. SRNT Newsletter Vol. 5 (3), October 1999. Bates No. 521955007/5025. Available at: http://legacy.library. ucsf.edu/tid/trb90d00.
135. Duke University.Third Annual Duke Nicotine Research Conference, Nicotinic Systems: Molecular Heterogenecity And Individual Differences Program. Bates No.2063126391/6401. Available at: http://legacy.library.ucsf. edu/tid/ltf33e00.
136. Lipowicz PJ. 6th Duke Nicotine Research Conference Trip Report. Bates No. 2715200604. Available at: http://legacy.library.ucsf.edu/tid/ege18c00.
137. Lukas RJ, Bencherif M, Eisenhour CM. Regulation by Nicotine of its Own Receptors. March 11, 1996. Bates No. 520924868/4870. Available at: http://legacy.library.ucsf.edu/tid/mof11d00.
138. Bero LA, Galbraith A, Rennie D. Sponsored symposia on environmental tobacco smoke. JAMA. 1994;271:612-617.
139. Cloninger CR. The State of Texas vs. the American Tobacco Company, et al. Videotaped Oral Deposition of C. Robert Cloninger. July 30, 1997. Bates No. 524800001/0218. Available at: http://legacy.library.ucsf.edu/tid/nvq20d00.
140. Holtzman A. Memo to Horace Kornegay about Tax-Free Cigarettes for Patient Treatment. February 5, 1975. Bates No. TCAL0004383. Available at: http://legacy.library.ucsf.edu/tid/mkn96d00.
141. Torrey EF. Cigarette Donation Request for Long-Term Psychiatric Patients. August 4, 1980. Bates No. 502358650. Available at: http://legacy.library.ucsf.edu/tid/xjg19d00.
142. RJ Reynolds Collection. Letter Declining Request for Cigarette Supply at Saint Elizabeth's Hospital. October 3, 1980. Bates No. 502358644. Available at: http://legacy.library.ucsf.edu/tid/aim18c00.
143. Buckingham J. Cigarette Request for Day Treatment Program for Mentally Ill Adults. September 11, 1992. Bates No. 508467552. Available at: http://legacy.library.ucsf.edu/tid/vjb38c00.
144. Hayworth P. Cigarette donation request for chronically mentally ill clients. January 22, 1996. Bates No. 524108319/8322. Available at: http://legacy.library.ucsf.edu/tid/ojj70d00.
145. Robertson ES. Hawaii State Hospital Request to RJ Reynolds for Cigarettes. October 4, 2000. Bates No. 522700931/0932. Available at: http://legacy.library.ucsf.edu/tid/xsm70d00.
146. Ardery PP. Kentucky's Legislators Thank You Letter. April 19, 1985. Bates No. 516001701. Available at: http://legacy.library.ucsf.edu/tid/ ejr24f00.
147. Reynolds RJ. West Palm Beach/Ft. Lauderdale Fax for Conference Invites. December 15, 1987. Bates No. 506131373/1381. Available at: http://legacy.library.ucsf.edu/tid/myo84d00.
148. Shook, Hardy, Bacon. Report on Recent ETS and IAQ Developments. February 24, 1992. Bates No. 2050751036/1069. Available at: http://legacy. library.ucsf.edu/tid/lgn32d00.
149. Shook, Hardy, Bacon. Report on Recent ETS and IAQ Developments. September 22, 1995. Bates No. 2046363816/3823. Available at: http://legacy.library.ucsf.edu/tid/iqt45d00.
150. Lyons J. Support of Region III Public Smoking Issues. May 9, 1989. Bates No. TIDN0003235/3236. Available at: http://legacy.library.ucsf.edu/tid/ duq91f00.
151. Doyle JR. Memo to Kent Wold Including the Maine Public Health Association Bulletin. March 29, 1991. Bates No. 507601201/1203. Available at: http://legacy.library.ucsf.edu/tid/vci24d00.
152. Doyle JR. Letter to Lawrence Tilton about Smoking in Restaurants Bill (L.D. 603) Being Set for Hearing on Wednesday, April 3, 1991. March 21, 1991. Bates No. 507601208. Available at: http://legacy.library.ucsf.edu/tid/ wci24d00.
153. Payne T. Hospital Accreditation.April 8, 1991. Bates No. 507687499/7500. Available at: http://legacy.library.ucsf.edu/tid/fqa24d00.
154. Mental Illness Advocacy Group Battling Hospital Smoking Ban in New York from Psychiatric News. September 16, 1994. Bates No. 2071540448. Available at: http://legacy.library.ucsf.edu/tid/cic60c00.
155. Alliance for the Mentally Ill, Friends & Advocates of the Mentally Ill. AMI/ FAMI Policy Paper on Nicotine Addiction and Psychiatric Patients. March 28, 1995. Bates No. 2071540442. Available at: http://legacy.library.ucsf.edu/tid/gic60c00.
156. Alliance for the Mentally Ill, Friends & Advocates of the Mentally Ill. Plea for Freedom to Smoke for Bellevue Hospital Psychiatric Patients. March, 1995. Bates No. 2071540428. Available at: http://legacy.library.ucsf.edu/tid/sic60c00.
157. Miller MW. Mental Patients Fight to Smoke in the Hospital. Wall St J. October 11 1994. Bates No. 2071540445. Available at: http://legacy. library.ucsf.edu/tid/eic60c00.
158. Konopka H. Note to Philip Morris. January 1995. Bates No. 2071540439. Available at: http://legacy.library.ucsf.edu/tid/jic60c00.
159. Konopka H. Hellen Konopka AMI and FAMI Business Card. January, 1995. Bates No. 2071540426. Available at: http://legacy.library.ucsf.edu/tid/ kic60c00.
160. Philip Morris Collection. Hearing Report/Bill Signing Report.January 10, 1995. Bates No. 2044332448/2451. Available at: http://legacy.library.ucsf.edu/tid/uim38d00.
161. Connelly, McLaughlin. Witnesses for Smoke-Free Air Act Hearing. Bates No. 2045959527. Available at: http://legacy.library.ucsf.edu/tid/tkq91a00.
162. Foderaro LW. Battling demons, and nicotine hospitals' smoking bans are new anxiety for mentally ill. NY Times. February 19, 1995. Bates No. 2071540443/0444. Available at: http://legacy.library.ucsf.edu/tid/fic60c00.
163. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53:1166-1170.
164. Prochaska JJ, Gill P, Hall SM. Treatment of tobacco use in an inpatient psychiatric setting. Psychiatr Serv. 2004;55:1265-1270.
165. Prochaska JJ, Fletcher L, Hall SE, Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. Am J Addict. 2006;15:15-22.
166. Yano E. Japanese spousal smoking study revisited: how a tobacco industry funded paper reached erroneous conclusions. Tob Control. 2005;14:227-233; discussion 233-235.
167. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998;279:1566-1570.
168. US Department of Health Education and Welfare. Smoking and Health: Report of the Advisory Committee of the Surgeon General of the Public Health Service. Washington, DC: US Government Printing Office; 1964.
169. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63:630-638.
170. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:8.
171. Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology. 2006;31:637-643.
172. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarksi P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55:850-858.
173. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2007; Available at: http://www.ncbi.nlm.nih.gov/sites/entrez.
174. Scriabine A. CNS FORUM Advancements in clinical trials and drug development Philadelphia, PA, USA, July 29-30, 2003. CNS Drug Rev. 2003;9:389-395.
175. Targacept. Press Release: Targacept announces initiation of phase IIb development of AZD3480 (TC-1734) for cognitive deficits in schizophrenia. August 23, 2007. Accessed at: http://www.targacept.com/wt/page/pr_1187809632.
176. Evins AE, Cather C, Deckersbach T, et al. A double-blind
177. Spiegel EP, Schrock DA, Smith MW. Effectiveness of a Transdermal Nicotine Replacement Intervention in Schizophrenic Smokers. New Orleans, La: American Psychological Association; 2006.
178. Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv. 2004;55:1064-1066.
179. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 1999;21:195-202.